| Phase 11 trial |
|
Phase 1
|
NCT05627232 |
Aug 2023 → Jan 2028 expected |
acute myeloid leukemia |
Thomas Jefferson University |
Recruiting
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT05554419 |
Jul → Aug 2026 overdue |
therapy related acute myeloid leukemia and myelodysplastic syndrome |
National Cancer Institute (NCI) |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05554406 |
Sep 2024 → Mar 2027 expected |
acute myeloid leukemia with multilineage dysplasia, therapy related acute myeloid leukemia and myelodysplastic syndrome |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05564390 |
Jun 2024 → May 2029 expected |
acute myeloid leukemia with multilineage dysplasia, myelodysplastic syndrome, therapy related acute myeloid leukemia and myelodysplastic syndrome |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03226418 |
Jul 2017 → Mar 2024 |
therapy related acute myeloid leukemia and myelodysplastic syndrome |
University of Nebraska |
Completed
|
No outcome recorded
|
| Comparator or background therapy2 trials |
|
Phase 1/2
|
NCT05320380 Background |
Aug → Sep 2023 |
B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia |
Children's Oncology Group |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT04802161 Background |
Aug 2022 → Nov 2024 overdue |
acute myeloid leukemia with multilineage dysplasia, chronic myelomonocytic leukemia, myelodysplastic syndrome, therapy related acute myeloid leukemia and myelodysplastic syndrome |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|